Summary
Severe congestive heart failure (CHF) is often characterised by fluid retention. A (chronic) state of overhydration has a negative influence on both the quality of life and prognosis of these patients. Therefore, the use of diuretics remains a cornerstone in the treatment of heart failure. However, diuretic resistance, a failure to correct the hydration state adequately with the use of conventional dosages of loop diuretics, is a frequently occurring complication in the treatment of advanced stages of CHF.
Several intra- and extrarenal mechanisms may be involved in the development of diuretic resistance. An important pathophysiological mechanism leading to diuretic resistance seen after chronic use of loop diuretics is the functional adaptation of the distal tubule. Studies in animals demonstrate that the sodium reabsorption capacity of this nephron segment increases significantly when the sodium delivery to this segment is augmented, as is the case during administration of loop diuretics.
The use of combinations of diuretics acting on different segments of the nephron appears to be an effective option in the treatment of diuretic resistance. Several combinations have been used; however, the combination of a loop diuretic and a thiazide drug acting on the distal tubule appears to be the most effective. However, since the use of this combination may lead to serious adverse effects such as hypokalaemia, metabolic alkalosis and dehydration, careful monitoring of the patient on combination diuretic therapy is necessary.
Similar content being viewed by others
References
Guidelines for the evaluation and management of heart failure: a report of the American Heart Association Task Force on Practice Guidelines. Circulation 1995; 92: 2764–84
Reitsma JB, Mosterd A, Craen de AJM, et al. Increase in hospital admission rates for heart failure in the Netherlands, 1980–1993. Heart 1996; 76: 388–92
Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993; 68: 1143–50
Packer M. Treatment of chronic heart failure. Lancet 1992; 340: 92–5
Packer M. Pathophysiology of chronic heart failure. Lancet 1992; 340: 88–92
Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol 1989; 63: 461–4
Vasko MR, Cartwright DB, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985; 102: 314–8.
Brater DC, Seiwell R, Anderson S, et al. Absorption and disposition of furosemide in congestive heart failure. Kidney Int 1982; 22: 171–6
Chennavasin P, Seiwell R, Brater DC. Pharmacokinetic-pharmacodynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther 1980; 215: 77–81
Cody RJ, Kubo SH and Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994; 154: 1905–14
Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886–94
Kelly RA, Smith TW. Drugs used in the treatment of heart failure. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders Co., 1997: 471–91
Hall JE. Control of glomerular filtration rate and sodium excretion by angiotensin II. Fed Proc 1986; 45: 1431–6
Blantz RC. The glomerular and tubular actions of angiotensin II. Am J Kidney Dis 1987; 10 Suppl. I: 2–10
Mancia G. Neurohumoral activation in congestive heart failure. Am Heart J 1990; 120: 1532–7
Mancia G. Sympathetic activation in congestive heart failure. Eur Heart J 1990; 11 Suppl. A: 3–11
Kon V, Yared A, Ichikawa I. Role of sympathetic nerves in mediating hypoperfusion of renal cortical microcirculation in experimental congestive heart failure and acute extracellular volume depletion. J Clin Invest 1985; 76: 1913–20
Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 1980; 28: 182–6
Wakelkamp M, Alvan G, Gabrielsson J, et al. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996; 60: 75–88
Wilcox CS, Guzman NJ, Mitch WE, et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987; 31: 135–41
Kaissling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery: I. Ultrastructure. Am J Physiol 1988; 255: F1256–68
Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Physiol 1988; 255: F1269–75
Morsing P, Velazquez H, Wright FS, et al. Adaptation of distal convoluted tubule of rats: II. Effects of chronic thiazide infusion. Am J Physiol 1991; 261: F137–43
Stanton BA, Kaissling B. Regulation of renal ion transport and cell growth by sodium. Am J Physiol 1989; 257: F1–10
Loon NR, Wilcox CS and Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989; 36: 682–9
Ellison DH, Velazquez H, Wright FS. Thiazide-sensitive sodium chloride cotransport in early distal tubule. Am J Physiol 1987; 253: F546–54
Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183–9
Sigurd B, Olesen KH. The supra-additive natriuretic effect addition of theophylline ethylenediamine and bumetanide in congestive heart failure: permutation trial tests in patients in long-term treatment with bumetanide. Am Heart J 1977; 94: 168–74
Knauf H, Mutschier E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 1997; 29: 367–72
Olesen KH, Dupont B, Flensted Jensen E. The combined diuretic action of quinethazone and furosemide in congestive heart failure: a permutation trial test. Acta Med Scand 1970; 187: 33–40
Gunstone RF, Wing AJ, Shani HG, et al. Clinical experience with metolazone in fifty-two African patients: synergy with frusemide. Postgrad Med J 1971; 47: 789–93
Sigurd B, Olesen KH, Wennevold A. The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure: permutation trial tests in patients in long-term treatment with bumetanide. Am Heart J 1975; 89: 163–70
Ghose RR, Gupta SK. Synergistic action of metolazone with ‘loop’ diuretics. Br Med J Clin Res Ed 1981; 282: 1432–3
Epstein MR, Lepp BA, Hoffman A, et al. Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977; 21: 656–67
Wollam GL, Tarazi RC, Bravo EL, et al. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982; 72: 929–38
Brater DC, Pressley RH, Anderson SA. Mechanisms of the synergistic combination of metolazone and bumetanide. J Pharmacol Exp Ther 1985; 233: 70–4
Reubi FC. Combination diuretic drug therapy. Cardiovasc Clin 1971; 2: 197–210
Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983; 99: 405–6
Kiyingi A, Field MJ, Pawsey CC, et al. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990; 335: 29–31
Channer KS, Richardson M, Crook R, et al. Thiazides with loop diuretics for severe congestive heart failure. Lancet 1990; 335: 922–3
Fliser D, Schroter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46: 482–8
Dormans TPJ, Gerlag PGG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 1996; 17: 1867–74
Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997; 18: 736–53
Ellison DH, Velazquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989; 83: 113–26
Channer KS, McLean KA, Law son-Matthew P, et al. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994; 71: 146–50
van Vliet AA, Donker AJ, Nauta JJ, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71: 21A-8A
Gerlag PG, van Meijel JJ. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988; 148: 286–91
Rybak LP. Furosemide ototoxicity: clinical and experimental aspects. Laryngoscope 1985; 95: 1–14
Brater DC. Resistance to loop diuretics: why it happens and what to do about it. Drugs 1985; 30: 427–43
Hammarlund Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease — an update. J Pharmacokinet Biopharm 1989; 17: 1–46
Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22: 69–74
Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115: 360–6
Dormans TPJ, van Meyel JJM, Gerlag PGG, et al. Diuretic efficacy of high-dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376–82
Ferguson JA, Sundblad KJ, Becker PK, et al. Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther 1997; 62: 203–8
Knauf H, Mutschier E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995; 26: 394–400
van Meyel JJ, Smits P, Dormans T, et al. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med 1994; 235: 329–34
Simpson IA, Rae AP, Simpson K, et al. Ultrafiltration in the management of refractory congestive heart failure. Br Heart J 1986; 55: 344–7
Rimondini A, Cipolla CM, Delia Bella P, et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med 1987; 83: 43–8
Rubin J, Ball R. Continuous ambulatory peritoneal dialysis as treatment of severe congestive heart failure in the face of chronic renal failure. Report of eight cases. Arch Intern Med 1986; 146: 1533–5
Dormans TPJ, Huige RMC, Gerlag PGG. Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart 1996; 75: 349–51
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dormans, T.P.J., Gerlag, P.G.G., Russel, F.G.M. et al. Combination Diuretic Therapy in Severe Congestive Heart Failure. Drugs 55, 165–172 (1998). https://doi.org/10.2165/00003495-199855020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199855020-00001